A5045670510- Cancer and Skin Lesions
- Salivary Gland Tumors Diagnosis and Treatment
- Nonmelanoma Skin Cancer Studies
- Oral and Maxillofacial Pathology
- Tumors and Oncological Cases
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Lung Cancer Research Studies
- Blood Pressure and Hypertension Studies
- Polyomavirus and related diseases
- Cardiac, Anesthesia and Surgical Outcomes
- Hormonal Regulation and Hypertension
- Mitochondrial Function and Pathology
- Bone Tumor Diagnosis and Treatments
- Genetic Neurodegenerative Diseases
- Cancer Diagnosis and Treatment
- Genetic and rare skin diseases.
- Sarcoma Diagnosis and Treatment
- Soft tissue tumor case studies
- Neurological disorders and treatments
- Lung Cancer Treatments and Mutations
Centre Hospitalier De Pau
2016-2024
Bordeaux Population Health
2024
Université de Tours
2023
Aims Porocarcinoma is a malignant sweat gland tumour differentiated toward the upper part of duct and may arise from transformation preexisting benign poroma. In 2019, Sekine et al. demonstrated presence YAP1::MAML2 YAP1::NUTM1 fusions in most poromas porocarcinomas. Recently, our group identified PAK2‐ subset poromas. Herein we report series 12 porocarcinoma cases harbouring PAK1/2/3 fusions. Methods Results Five patients were male median age was 79 years (ranges: 59–95). Tumours located on...
Recurrent oncogenic drivers have been identified in a variety of sweat gland tumors. Recently, integration human papillomavirus type 42 (HPV42) has reported digital papillary adenocarcinoma (DPA). The main objectives the present study were (i) to provide an overview prevalence previously acral tumors and (ii) genetically characterize which no recurrent genetic alteration yet. Cases from database French network CARADERM. After histologic review, presence alterations was investigated entire...
The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been thoroughly described in the literature.In this retrospective multicenter national real-life study, we enrolled patients who had rechallenged with an after achieving a first course ICI, which was subsequently interrupted. primary objective to evaluate tumor response, while secondary objectives included...
Digital papillary adenocarcinoma (DPA) is a rare sweat gland neoplasm that has exceptionally been reported outside acral locations. Recently, human papillomavirus 42 was identified as the main oncogenic driver of DPA. Herein, we report 5 tumors arising in extra-acral locations predominantly female anogenital skin. Four patients were and 1 patient male. The mean age at diagnosis time 65 years (range: 55 to 82 y). Tumors located on vulva (n=3), perianal area (n=1), forearm (n=1)....
We report 21 cases of trichogerminoma harbouring previously undescribed FOXK1::GRHL1/2 or GPS2::GRHL1/2/3 in-frame fusion transcripts. Microscopic examination a preliminary set five revealed well-delimitated tumours located in the dermis with frequent extension to subcutaneous tissue. Tumours presented massive and nodular architecture consisted proliferation basaloid cells. A biphasic pattern sometime resulting tumour cell nests ('cell balls') was present. Immunohistochemistry demonstrated...
Background: Malignant hypertension has not disappeared and remains the most severe form of hypertension. More than 100 years after its description, many points remain unanswered. Mechanisms, definitions, optimal treatment are still controversial. In 2019, we decided to launch a prospective multicentre multidisciplinary cohort in France try fill these gaps. Method: This study aimed describe baseline characteristics first 302 included patients compared data already published cohorts. We with...
9529 Background: The efficacy of ICI rechallenge for progressive/recurrent disease advanced melanoma patients (pts) after a first course interrupted control has not been systematically described. Methods: A retrospective observational multicenter national real-life study evaluated the and tolerance (anti-PD1, anti-CTLA-4, or combination therapy) in pts who progressed with an subsequently interrupted. Primary objective was to evaluate tumor response using RECIST version 1.1. Secondary...